Testosterone Therapy for Women: What the Evidence Actually Supports

Searches for “testosterone cream for women” have climbed alongside the broader hormone-optimization wave, often framed as a fix for low energy, brain fog, mood, or midlife weight. The evidence tells a narrower and more useful story. A large international panel reviewed the randomized trial data and reached a single, carefully bounded conclusion: low-dose testosterone helps one specific problem in one specific group of women, and is not supported for the long list of “wellness” uses it is most often sold for.^[1] This piece walks through what the data actually support, what they do not, and why the way testosterone is delivered to women is its own safety issue.

The one evidence-based indication

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women — endorsed by endocrine, menopause, and sexual-medicine societies and published simultaneously across several journals — concluded that the only evidence-based indication is the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women, after other contributing factors have been addressed.^[1] HSDD is persistent, distressing low sexual desire that is not better explained by a relationship problem, another medical condition, or a medication. Outside that diagnosis, the statement does not endorse testosterone for women.^[1]

How large is the effect?

The systematic review and meta-analysis of randomized controlled trial data that underpinned the consensus found that testosterone, compared with placebo or a comparator, produced a modest but real improvement in sexual function in postmenopausal women — including measures of desire, arousal, orgasm, and satisfaction, with fewer distressing low-desire episodes.^[2] The word that recurs in the data is modest: this is a measurable benefit for a defined complaint, not a transformation. Honest counseling sets that expectation up front.^[2]

What the evidence does NOT support

This is where most consumer marketing diverges from the science. The meta-analysis and the consensus both found insufficient evidence to recommend testosterone in women for cognition or memory, mood or depressive symptoms, general well-being or energy, bone density, muscle performance, cardiovascular protection, or broad “anti-aging” and metabolic goals.^[1][2] The panel was explicit that data are either lacking or do not show benefit for these outcomes, so testosterone should not be prescribed for them.^[1] The popular “T for energy and mood” pitch for women is, on the current evidence, off-label and unsupported.

There is no FDA-approved product for women

A structural problem sits underneath all of this: in the United States there is no testosterone formulation approved for use in women. The consensus notes the absence of an approved female product and that, in practice, treatment relies on off-label use of formulations made for men — dosed down to roughly a tenth of a male dose — or on compounded preparations.^[1] Splitting a product designed to deliver a male dose into a precise female microdose is inherently imprecise, which is exactly why blood-level monitoring matters (below).

Route matters: transdermal, not oral

The consensus recommends that, when testosterone is used for postmenopausal HSDD, it be given by a non-oral (transdermal) route — a cream or gel applied to the skin — rather than orally.^[1] Oral testosterone undergoes first-pass liver metabolism and has been associated with adverse effects on lipids, whereas transdermal delivery avoids that and keeps exposure steadier.^[1] So a low-dose testosterone creamis the route the evidence points to — but the indication still has to be HSDD, and the dose still has to be small.

Keep blood levels in the female range

Because the therapeutic target is a physiologic female level — not a high “optimized” one — the consensus advises measuring testosterone before treatment and monitoring during it, with the goal of keeping concentrations within the premenopausal physiologic range and avoiding supraphysiologic (male-range) levels.^[1] The benefit demonstrated in trials occurred at these modest doses; pushing levels higher does not buy more sexual-function benefit and does add risk.^[2]

Virilization, pellets, and compounded creams

At physiologic doses, mild side effects such as acne or increased hair growth can occur but are generally limited; the serious problems — deepening of the voice, clitoral enlargement, scalp hair loss, and unwanted body-hair growth, some of which may not fully reverse — cluster at supraphysiologic exposure.^[1] This is the core argument against subcutaneous testosterone pellets and high-dose compounded products: the consensus specifically cautions that compounded “bioidentical” testosterone and pellet or injectable formulations can deliver inconsistent or supraphysiologic doses, and it does not recommend them.^[1] A pellet that releases too much testosterone for months cannot be dialed back the way a daily cream can, which is why the dosing-precision problem becomes a safety problem.

The honest verdict

The evidence supports low-dose transdermal testosterone for one purpose: hypoactive sexual desire disorder in postmenopausal women, where it delivers a modest but genuine improvement in sexual function, dosed to keep blood levels within the female physiologic range.^[1][2] It does not support testosterone for energy, mood, cognition, bone, cardiovascular health, or general anti-aging in women.^[1]With no FDA-approved female product, treatment means careful off-label dosing of a male product or a compounded cream — and compounded high-dose creams and pellets carry a real overdosing and virilization risk that the global consensus explicitly advises against.^[1] If you are considering it, the conversation worth having is about HSDD specifically, a transdermal route, and baseline-plus-follow-up blood testing — not about “optimizing” a number.